Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer
Abstract Background The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain uncertain, along with the specific patient subgroups that may gain the most from this approach. This retrospective study aim...
Saved in:
| Main Authors: | Jing Cheng, Wenwen Kang, Yueying Chen, Luyun Pan, Hedong Han, Tangfeng Lv |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-03958-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report
by: Heng-Xu Lyu, et al.
Published: (2024-09-01) -
Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study
by: Šejla Cerić, et al.
Published: (2025-03-01) -
Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
by: Hong Huang, et al.
Published: (2025-04-01) -
Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database
by: Dipesh Uprety, et al.
Published: (2025-02-01) -
Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)